Post-market surveillance shows continued low complication rates with OssDsign Cranial PSI

Uppsala, December 2, 2021. OssDsign AB (publ.) today announces updated clinical data from a long-term follow-up of the company's innovative product OssDsign Cranial PSI, which is used in the treatment of cranial bone defects. The data, based on 1,480 surgeries, shows that the frequency of infections leading to implant removal was 1.6% after a median follow-up time of 22 months. This positive outcome exceeds what has been observed in previous follow-ups, thus highlighting the exceptional performance of OssDsign Cranial PSI.OssDsign Cranial PSI is a patient-specific cranial implant made from